Search BioPortfolio:
BioPortfolio
Web
Home
Marketing Services
News
Reports
Company Profiles
InDepth
Drug Discovery
Careers
Conferences
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
The Rise of Mid-Sized Pharma
2.
Contract Research Annual Review 2008
3.
Amgen - The Biotech Leader - Market Analyses and Outlook, 2008-2023
4.
The World OTC Pharmaceutical Market Analysis and Forecasts, 2008-2023
5.
Monoclonal Antibodies Report: 2008 Update
6.
Pipeline and Commercial Insight: Neuropathic Pain - UCB's Vimpat set to compete with major players
7.
Stakeholder Opinions: Non-hormonal Treatments for Menopausal Symptoms - Market open to takers as tepid pipeline fails to meet demand
8.
Rx-to-OTC Strategies: Maximizing the Commercial Potential of an Rx-to-OTC Switch
9.
Drug Repositioning Strategies - Serendipity by design
10.
Forecast Insight: Osteoarthritis - The COX-2 pipeline collapses
Best Sellers:
1.
BioNewsCast Press Release Distribution Service
2.
Immunogenicity to Biologics Implications of reactions against biotech drugs
3.
Outsourcing in Drug Discovery, 3rd Edition
4.
American Hospital Register
5.
Professional Designation in Biopharmaceutical Technology - 3 Course Curriculum
6.
Outlook for RNAi, 2007 - siRNA and miRNA in biology, diagnostics and therapeutics
Infertility - Optimizing a market bounded by social opinion and physician preference
"IntroductionThe market for infertility drugs is a complex and dynamic arena shaped by numerous factors such as changing social attitudes, national legislation, and prescriber preferences. Brand strength and diverse portfolios have allowed Organon, Merck Serono and Ferring to secure a firm foothold in the market, worth over $1 billion in 2006, and represent tough competition.ScopeAnalysis of patient potential, unmet needs, market dynamics, and clinical trial design in infertility, supported by opinion leader comment Assessment of pipeline drugs and future treatment trends and their impact on prescribing patterns and behavior Patient based and sales based market forecasts to 2016, the latter providing a breakdown by region, drug class, marketed brands and pipeline drugs Coverage of emerging infertility markets which, in light of reproductive tourism, may offer revenue growth potentialHighlightsKey differentiators will permit Organon's Org-36286 (corifollitropin alpha) and Merck Serono's Pergoveris (r-FSH and r-LH), to cannibalize some share from their proprietors' franchise leading therapies. However, these agents do not appear to satisfy unmet need and this will prevent sales from rivaling Puregon and Menopur (hMG). The lack of education of non-specialist physicians limits the number of women receiving treatment. It should be a primary goal of the market to make these doctors more knowledgeable and to implement incentives to encourage patient referral. New opportunities exist in the development of products to support embryological techniques; cryopreservation, microarrays and in vitro maturation. These procedures will expand the treatable patient population as all women with the intention of preserving and protecting embryos will be eligible for treatment, not just those that are infertile.Reasons to PurchaseQuantify the future size of the infertility market and the number of women eligible for infertility treatment to 2016 in the US, 5EU, and Japan Understand unmet needs and opportunities in the infertility market based on key opinion leader comments Benchmark key late-stage infertility compounds against current market leading brands"
10-Oct-07 Format: PDF & DataPack Pages: 189
Table fo Contents
Price: $15,200.00 / GBP7,600.00
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.